[go: up one dir, main page]

ECSP20080817A - Inhibidores de moléculas pequeñas de la familia de quinasas jak - Google Patents

Inhibidores de moléculas pequeñas de la familia de quinasas jak

Info

Publication number
ECSP20080817A
ECSP20080817A ECSENADI202080817A ECDI202080817A ECSP20080817A EC SP20080817 A ECSP20080817 A EC SP20080817A EC SENADI202080817 A ECSENADI202080817 A EC SENADI202080817A EC DI202080817 A ECDI202080817 A EC DI202080817A EC SP20080817 A ECSP20080817 A EC SP20080817A
Authority
EC
Ecuador
Prior art keywords
kinases
small molecule
molecule inhibitors
jak family
methods
Prior art date
Application number
ECSENADI202080817A
Other languages
English (en)
Inventor
Paul J Krawczuk
Mark S Tichenor
Philippe Fernandes
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP20080817A publication Critical patent/ECSP20080817A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de 2-((1r,4r)-4-(imidazo[4,5-d]pirrolo[2,3-b]piridin-1(6H)-il)ciclohexil)acetonitrilo, composiciones farmacéuticas que los contienen, métodos para elaborarlos y métodos para usarlos que incluyen métodos para tratar estados de enfermedad, trastornos y condiciones mediados por JAK.
ECSENADI202080817A 2018-06-15 2020-12-14 Inhibidores de moléculas pequeñas de la familia de quinasas jak ECSP20080817A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862685737P 2018-06-15 2018-06-15
US201962846290P 2019-05-10 2019-05-10

Publications (1)

Publication Number Publication Date
ECSP20080817A true ECSP20080817A (es) 2021-01-29

Family

ID=67766195

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202080817A ECSP20080817A (es) 2018-06-15 2020-12-14 Inhibidores de moléculas pequeñas de la familia de quinasas jak

Country Status (23)

Country Link
US (3) US20200017498A1 (es)
EP (1) EP3807277A1 (es)
JP (1) JP2021528391A (es)
KR (1) KR102768284B1 (es)
CN (1) CN112313233A (es)
AU (1) AU2019286641A1 (es)
BR (1) BR112020024744A2 (es)
CA (1) CA3101438A1 (es)
CL (1) CL2020003227A1 (es)
CO (1) CO2020015396A2 (es)
CR (1) CR20200603A (es)
EC (1) ECSP20080817A (es)
IL (1) IL279314A (es)
JO (1) JOP20200311A1 (es)
MA (1) MA52900A (es)
MX (1) MX2020013688A (es)
NI (1) NI202000100A (es)
PE (1) PE20212113A1 (es)
PH (1) PH12020551984A1 (es)
SG (1) SG11202011691PA (es)
TW (1) TW202016110A (es)
UY (1) UY38262A (es)
WO (1) WO2019239387A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112379A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Small molecule inhibitors of the jak family of kinases
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
CA3213134A1 (en) 2021-03-11 2022-09-15 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN113292561A (zh) * 2021-05-22 2021-08-24 中国药科大学 一种二吡咯并吡啶结构的化合物、制备方法和医药用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
MXPA01010821A (es) 1999-04-23 2003-09-04 Smithkline Beecham Plc Forma poliformica de sal de acido maleico de 5-[4-[2 -(n-metil -n-(2- piridil) amino ) etoxi] bencil ] tiazolidin-2, 4-diona.
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
AU2003249658A1 (en) 2002-05-31 2003-12-19 Schering Corporation Xanthine phosphodiesterase v inhibitor polymorphs
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
MX2008000384A (es) 2005-07-01 2008-03-07 Wyeth Corp Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metox i-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y metodos para su preparacion.
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
TW201612182A (en) 2008-06-10 2016-04-01 Abbvie Inc Novel tricyclic compounds
KR101669311B1 (ko) 2009-09-03 2016-10-25 브리스톨-마이어스 스큅 컴퍼니 Ｊａｋ２ 억제제, 및 골수증식성 질환 및 암의 치료를 위한 그의 용도
SG10201407976UA (en) 2009-12-01 2015-01-29 Abbvie Inc Novel tricyclic compounds
KR20120102724A (ko) 2009-12-01 2012-09-18 아보트 러보러터리즈 신규한 트리사이클릭 화합물
EP2523957A1 (en) * 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Tricyclic heterocyclic compounds, compositions and methods of use thereof
AU2011214254B2 (en) 2010-02-10 2016-06-09 Genon Biotechnologies Oy Dual activity kinase domains and uses thereof
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
WO2014123167A1 (ja) 2013-02-08 2014-08-14 日産化学工業株式会社 ３環性ピロロピリジン化合物及びｊａｋ阻害剤
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
CN106459050B (zh) 2014-05-14 2019-02-26 日产化学株式会社 三环化合物以及jak抑制剂
EP3303348B1 (en) 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Naphthyridine compounds as jak kinase inhibitors
EP3371332A4 (en) 2015-11-04 2019-04-03 Mayo Foundation for Medical Education and Research METHOD AND MATERIALS FOR TREATING AUTOIMMUNE DISEASES
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
CN114656464B (zh) 2016-10-24 2024-10-15 阿斯利康(瑞典)有限公司 可用于治疗癌症的6,7,8,9-四氢-3H-吡唑并[4,3-f]异喹啉衍生物
WO2018112379A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Small molecule inhibitors of the jak family of kinases
EP3528645A1 (en) 2016-12-16 2019-08-28 Société des Produits Nestlé S.A. Oligosaccharides for flavour generation
LT3555064T (lt) 2016-12-16 2023-01-10 Pfizer Inc. Glp-1 receptoriaus agonistai ir jų naudojimas
EP3555105B1 (en) 2016-12-16 2020-10-28 Eli Lilly and Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
KR20190092539A (ko) 2016-12-16 2019-08-07 바스프 에스이 살충 화합물
RU2019125177A (ru) 2017-01-11 2021-02-15 Лео Фарма А/С Новые производные амино-имидазопиридина в качестве ингибиторов янус-киназы и их фармацевтическое применение
WO2018138303A1 (en) 2017-01-30 2018-08-02 Astrazeneca Ab Estrogen receptor modulators
CN110831600B (zh) 2017-04-21 2023-10-17 医肯纳肿瘤学公司 吲哚ahr抑制剂和其用途
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020216936A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor

Also Published As

Publication number Publication date
IL279314A (en) 2021-01-31
MX2020013688A (es) 2021-02-26
US20200165250A1 (en) 2020-05-28
KR20210021342A (ko) 2021-02-25
PH12020551984A1 (en) 2021-08-02
BR112020024744A2 (pt) 2021-03-23
US11066406B2 (en) 2021-07-20
PE20212113A1 (es) 2021-11-04
AU2019286641A1 (en) 2020-12-10
UY38262A (es) 2019-12-31
NI202000100A (es) 2021-06-30
WO2019239387A1 (en) 2019-12-19
CN112313233A (zh) 2021-02-02
KR102768284B1 (ko) 2025-02-13
US20200017498A1 (en) 2020-01-16
CR20200603A (es) 2021-01-20
JOP20200311A1 (ar) 2020-11-30
CO2020015396A2 (es) 2021-03-08
CL2020003227A1 (es) 2021-05-14
TW202016110A (zh) 2020-05-01
CA3101438A1 (en) 2019-12-19
US11787807B2 (en) 2023-10-17
US20210340144A1 (en) 2021-11-04
EP3807277A1 (en) 2021-04-21
MA52900A (fr) 2021-04-21
JP2021528391A (ja) 2021-10-21
SG11202011691PA (en) 2020-12-30

Similar Documents

Publication Publication Date Title
ECSP19047936A (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak
ECSP19042688A (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak
ECSP20080817A (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak
EA201991109A1 (ru) ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
EA201991094A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
EA201990973A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
AR114969A1 (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak
EA201991473A1 (ru) Имидазопирролопиридин в качестве ингибиторов киназ семейства jak
EA202190047A1 (ru) Низкомолекулярные ингибиторы киназ семейства jak
EA201991472A1 (ru) Низкомолекулярные ингибиторы киназ семейства jak
CR20190283A (es) Imidazopyrrolopyridine as inhibitors of the jak family of kinases
MA50430B1 (fr) Composés d'imidazo[4,5-d]pyrrolo[2,3-b]pyridine comme inhibiteurs de janus kinases
TH1901003656A (th) สารยับยั้งที่มีโมเลกุลขนาดเล็กของวงศ์ jak ของไคเนส